The new AF2 facility has been designed to meet cGMP (Current Good Manufacturing Practice) requirements, to deliver a new standard for safety and quality for cell culture media and supplements.
Products manufactured in the new plant will be controlled for animal-origin component raw materials to the tertiary level. The new facility integrates cell culture media and supplement manufacturing capabilities, with the ability to produce complete formulations for the full range of expression systems for microbial fermentation, mammalian cell culture and stem cell culture, BD said.
BD Biosciences president William Rhodes said that the facility will help BD meet the growing worldwide demand for safe, high-yield cell culture media and supplements that are used in the production of biological medicines.
The new manufacturing facility is expected to create 50 jobs by 2013.
New Jersey-based BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines.